AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

RegulatoryapprovedNanoKnife IRE PlatformPositive

AI Analysis

Summary

AngioDynamics received FDA IDE (Investigational Device Exemption) approval for the RELIEF Feasibility Study to evaluate its NanoKnife IRE Platform as a minimally invasive treatment for benign prostatic hyperplasia.

Clinical Trial Data

Phase

Feasibility

Outcome Details

FDA IDE approval for RELIEF Feasibility Study

Importance:6/10

Sentiment:

0.70

FDA approvalIDEminimally invasivemedical deviceBPH

Related Companies

$ANGO

Read the original article

Published by yahoo_finance on June 17, 2026 12:30 PM

Read Original